On July 15, Pharmaron rose 6.02% in regular trading, trading at HK$24.68/share, with turnover of HK$124 million.

The rally was driven by the company's H1 earnings preview disclosed on July 13 and continued momentum across the CXO sector. Pharmaron forecast H1 revenue of RMB 7.47-7.67 billion, up 16%-19% YoY, with attributable net profit of RMB 729-772 million, up 4%-10% YoY. Adjusted non-IFRS net profit is expected at RMB 884-922 million, up 17%-22% YoY. The company highlighted newly signed orders growing over 30% YoY, with small-molecule CDMO orders surging over 50%. By mid-point estimates, Q2 revenue grew 19.38% YoY with sequential profit acceleration.

At the sector level, the CXO segment has sustained its rebound supported by strong orders and earnings, with the CRO index rallying 21.72% from June 8 to July 10. Daiwa recently initiated coverage with a Buy rating and HK$25.5 target price, citing recovery in global biopharma funding and robust CMC business growth prospects.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)